Literature DB >> 27054693

Increased Signal Intensity in the Dentate Nucleus of Patients with Multiple Sclerosis in Comparison with Neuromyelitis Optica Spectrum Disorder after Multiple Doses of Gadolinium Contrast.

Masami Tanaka1, Kazuki Nakahara, Masako Kinoshita.   

Abstract

AIMS: This study was conducted to compare the effect of linear gadolinium-based contrast agents in the retention in the cerebellar dentate nucleus of patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOsd).
METHODS: The signal intensity ratio of the pons to the cerebellar dentate nucleus was measured on T1-weighted MRI scans of the brain in 21 MS patients and 6 NMOsd patients given at least 10 doses of gadolinium. Linear regression analysis of the number of doses was then conducted for each patient.
RESULTS: The mean correlation coefficients of the MS and NMOsd patient groups were 0.0029 and -0.0017, respectively, with positive correlations observed in 17 out of 21 patients (81.0%) in the MS group and 2 out of 6 patients (33.3%) in the NMOsd group. Results suggested that significantly high levels of gadolinium accumulate in MS the more doses to the dentate nucleus are increased (p < 0.05).
CONCLUSION: Repeated doses of linear gadolinium cause accumulation of gadolinium in the cerebellar dentate nucleus, but differences observed between MS and NMOsd patients suggested that both the structure of gadolinium and differences in disease pathology affect accumulation.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27054693     DOI: 10.1159/000445431

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  11 in total

1.  Effects of serial macrocyclic-based contrast materials gadoterate meglumine and gadobutrol administrations on gadolinium-related dentate nuclei signal increases in unenhanced T1-weighted brain: a retrospective study in 158 multiple sclerosis (MS) patients.

Authors:  Alessandra Splendiani; Marco Perri; Claudia Marsecano; Valentina Vellucci; Giulia Michelini; Antonio Barile; Ernesto Di Cesare
Journal:  Radiol Med       Date:  2017-09-27       Impact factor: 3.469

Review 2.  Gadolinium retention in the body: what we know and what we can do.

Authors:  Enrico Tedeschi; Ferdinando Caranci; Flavio Giordano; Valentina Angelini; Sirio Cocozza; Arturo Brunetti
Journal:  Radiol Med       Date:  2017-03-30       Impact factor: 3.469

Review 3.  Standardized assessment of the signal intensity increase on unenhanced T1-weighted images in the brain: the European Gadolinium Retention Evaluation Consortium (GREC) Task Force position statement.

Authors:  Carlo C Quattrocchi; Joana Ramalho; Aart J van der Molen; Àlex Rovira; Alexander Radbruch
Journal:  Eur Radiol       Date:  2018-11-09       Impact factor: 5.315

Review 4.  Biological effects of MRI contrast agents: gadolinium retention, potential mechanisms and a role for phosphorus.

Authors:  Joel Garcia; Stephen Z Liu; Angelique Y Louie
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2017-11-28       Impact factor: 4.226

5.  The benefits and side effects of gadolinium-based contrast agents in multiple sclerosis patients.

Authors:  Elnaz Asadollahzade; Fereshteh Ghadiri; Zahra Ebadi; Abdorreza Naser Moghadasi
Journal:  Rev Assoc Med Bras (1992)       Date:  2022-08       Impact factor: 1.712

6.  Absence of T1 Hyperintensity in the Brain of High-risk Patients After Multiple Administrations of High-dose Gadobutrol for Cardiac Magnetic Resonance.

Authors:  Antonella Meloni; Domenico Montanaro; Daniele De Marchi; Mariachiara Resta; Petra Keilberg; Laura Pistoia; Vincenzo Positano; Anna Spasiano; Tommaso Casini; Caterina Cinzia De Bari; Sara De Cori; Alessia Pepe
Journal:  Clin Neuroradiol       Date:  2020-03-17       Impact factor: 3.649

7.  Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS.

Authors:  Robert Zivadinov; Niels Bergsland; Jesper Hagemeier; Deepa P Ramasamy; Michael G Dwyer; Ferdinand Schweser; Channa Kolb; Bianca Weinstock-Guttman; David Hojnacki
Journal:  Neurology       Date:  2019-07-08       Impact factor: 11.800

8.  The presence of the gadolinium-based contrast agent depositions in the brain and symptoms of gadolinium neurotoxicity - A systematic review.

Authors:  Cyprian Olchowy; Kamil Cebulski; Mateusz Łasecki; Radosław Chaber; Anna Olchowy; Krzysztof Kałwak; Urszula Zaleska-Dorobisz
Journal:  PLoS One       Date:  2017-02-10       Impact factor: 3.240

Review 9.  Gadolinium Deposition in the Brain: Current Updates.

Authors:  Jin Woo Choi; Won-Jin Moon
Journal:  Korean J Radiol       Date:  2018-12-27       Impact factor: 3.500

Review 10.  Gadolinium Deposition in Brain: Current Scientific Evidence and Future Perspectives.

Authors:  Bang J Guo; Zhen L Yang; Long J Zhang
Journal:  Front Mol Neurosci       Date:  2018-09-20       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.